tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Keay Nakae, 281 are a BUY (90.35%), 24 are a HOLD (7.72%), 6 are a SELL (1.93%).
Analyst Keay Nakae, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 44.4% that have a potential upside of 37.06% achieved within 164 days.
Keay Nakae’s has documented 551 price targets and ratings displayed on 48 stocks. The coverage is on Healthcare, Financial Services, Consumer Cyclical sectors.
Most recent stock forecast was given on IBIO, Ibio at 02-Jul-2026.
Analyst best performing recommendations are on STOK (STOKE THERAPEUTICS).
The best stock recommendation documented was for STOK (STOKE THERAPEUTICS) at 1/5/2026. The price target of $35 was fulfilled within 1 day with a profit of $2.45 (7.53%) receiving and performance score of 75.27.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Sep-2020
$5
$0.42 (9.17%)
$5
7 months 24 days ago
(14-Nov-2025)
4/14 (28.57%)
$0.48 (10.62%)
136
Buy Since 05-Nov-2021
$5
$0.42 (9.17%)
$5
1 years 3 months 7 days ago
(31-Mar-2025)
2/10 (20%)
$1.51 (43.27%)
256
Buy Since 17-Dec-2020
$5
$0.42 (9.17%)
$5
1 years 5 months 17 days ago
(21-Jan-2025)
0/18 (0%)
$1.79 (55.76%)
Buy Since 02-Feb-2022
$5
$0.71 (16.55%)
$4
4 years 5 months 6 days ago
(02-Feb-2022)
1/2 (50%)
$2.11 (73.01%)
980
Buy Since 05-Mar-2020
$7
5 years 10 days ago
(28-Jun-2021)
0/4 (0%)
$3.7 (112.12%)
Which stock is Keay Nakae is most bullish on?
Which stock is Keay Nakae is most reserved on?
What Year was the first public recommendation made by Keay Nakae?
